{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:41:56Z","timestamp":1794411716879,"version":"4.9.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11427-024-2946-1","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T11:55:22Z","timestamp":1756814122000},"page":"921-936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["circSCAP-encoded SCAP-129aa mediates platinum resistance in triple-negative breast cancer via the PI3K\/AKT pathway"],"prefix":"10.1007","volume":"69","author":[{"given":"Qi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangqiu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianfeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiye","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiquan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinna","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lok Lam","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huipei","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"2946_CR1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini, G., Balko, J.M., Mayer, I.A., Sanders, M.E., and Gianni, L. (2016). Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13, 674\u2013690.","journal-title":"Nat Rev Clin Oncol"},{"key":"2946_CR2","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1021\/jm401642q","volume":"57","author":"V Certal","year":"2014","unstructured":"Certal, V., Carry, J.C., Halley, F., Virone-Oddos, A., Thompson, F., Filoche-Romm\u00e9, B., El-Ahmad, Y., Karlsson, A., Charrier, V., Delorme, C., et al. (2014). Discovery and optimization of pyrimidone indoline amide PI3K\u03b2 inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers. J Med Chem 57, 903\u2013920.","journal-title":"J Med Chem"},{"key":"2946_CR3","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1016\/j.molcel.2021.07.042","volume":"81","author":"CK Chen","year":"2021","unstructured":"Chen, C.K., Cheng, R., Demeter, J., Chen, J., Weingarten-Gabbay, S., Jiang, L., Snyder, M.P., Weissman, J.S., Segal, E., Jackson, P.K., et al. (2021). Structured elements drive extensive circular RNA translation. Mol Cell 81, 4300\u20134318.e13.","journal-title":"Mol Cell"},{"key":"2946_CR4","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s11427-023-2343-y","volume":"66","author":"G Chen","year":"2023","unstructured":"Chen, G., Sun, L., Gu, X., Ai, L., Yang, J., Zhang, Z., Hou, P., Wang, Y., Ou, X., Jiang, X., et al. (2023). FSIP1 enhances the therapeutic sensitivity to CDK4\/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway. Sci China Life Sci 66, 2805\u20132817.","journal-title":"Sci China Life Sci"},{"key":"2946_CR5","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.jfma.2020.01.004","volume":"119","author":"YM Chen","year":"2020","unstructured":"Chen, Y.M., Chih-Hsin Yang, J., Su, W.C., Chong, I.W., Hsia, T.C., Lin, M.C., Chang, G. C., Chiu, C.H., Ho, C.C., Wu, S.Y., et al. (2020). Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: a phase II study in Taiwan. J Formos Med Assoc 119, 1817\u20131826.","journal-title":"J Formos Med Assoc"},{"key":"2946_CR6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari, S., and Bernard Tchounwou, P. (2014). Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740, 364\u2013378.","journal-title":"Eur J Pharmacol"},{"key":"2946_CR7","doi-asserted-by":"publisher","first-page":"116984","DOI":"10.1016\/j.lfs.2019.116984","volume":"239","author":"Y Dong","year":"2019","unstructured":"Dong, Y., Xu, T., Zhong, S., Wang, B., Zhang, H., Wang, X., Wang, P., Li, G., and Yang, S. (2019). Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p. Life Sci 239, 116984.","journal-title":"Life Sci"},{"key":"2946_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11912-019-0846-7","volume":"21","author":"H Ellis","year":"2019","unstructured":"Ellis, H., and Ma, C.X. (2019). PI3K inhibitors in breast cancer therapy. Curr Oncol Rep 21, 110.","journal-title":"Curr Oncol Rep"},{"key":"2946_CR9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11427-023-2425-2","volume":"67","author":"X Fan","year":"2024","unstructured":"Fan, X., Liu, F., Wang, X., Wang, Y., Chen, Y., Shi, C., Su, X., Tan, M., Yan, Q., Peng, J., et al. (2024). LncFASA promotes cancer ferroptosis via modulating PRDX1 phase separation. Sci China Life Sci 67, 488\u2013503.","journal-title":"Sci China Life Sci"},{"key":"2946_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/cancers3011351","volume":"3","author":"AM Florea","year":"2011","unstructured":"Florea, A.M., and B\u00fcsselberg, D. (2011). Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3, 1351\u20131371.","journal-title":"Cancers"},{"key":"2946_CR11","doi-asserted-by":"publisher","first-page":"e008037","DOI":"10.1136\/jitc-2023-008037","volume":"12","author":"S Frentzas","year":"2024","unstructured":"Frentzas, S., Austria Mislang, A.R., Lemech, C., Nagrial, A., Underhill, C., Wang, W., Wang, Z.M., Li, B., Xia, Y., and Coward, J.I.G. (2024). Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors. J Immunother Cancer 12, e008037.","journal-title":"J Immunother Cancer"},{"key":"2946_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman, D.A., Chiu, H., Hopkins, B.D., Bagrodia, S., Cantley, L.C., and Abraham, R.T. (2017). The PI3K pathway in human disease. Cell 170, 605\u2013635.","journal-title":"Cell"},{"key":"2946_CR13","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s11427-023-2499-2","volume":"67","author":"K Ganesan","year":"2024","unstructured":"Ganesan, K., Xu, C., Wu, J., Du, B., Liu, Q., Sui, Y., Song, C., Zhang, J., Tang, H., and Chen, J. (2024). Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K\/Akt\/mTOR pathway. Sci China Life Sci 67, 1849\u20131866.","journal-title":"Sci China Life Sci"},{"key":"2946_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro, A.C., Lin, N.U., and Polyak, K. (2019). Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 9, 176\u2013198.","journal-title":"Cancer Discov"},{"key":"2946_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jconrel.2021.07.014","volume":"337","author":"S Ghosh","year":"2021","unstructured":"Ghosh, S., Javia, A., Shetty, S., Bardoliwala, D., Maiti, K., Banerjee, S., Khopade, A., Misra, A., Sawant, K., and Bhowmick, S. (2021). Triple negative breast cancer and non-small cell lung cancer: clinical challenges and nano-formulation approaches. J Control Release 337, 27\u201358.","journal-title":"J Control Release"},{"key":"2946_CR16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1186\/s12885-019-6278-9","volume":"19","author":"DP Hill","year":"2019","unstructured":"Hill, D.P., Harper, A., Malcolm, J., McAndrews, M.S., Mockus, S.M., Patterson, S.E., Reynolds, T., Baker, E.J., Bult, C.J., Chesler, E.J., et al. (2019). Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance. BMC Cancer 19, 1039.","journal-title":"BMC Cancer"},{"key":"2946_CR17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1470-2045(15)70064-1","volume":"16","author":"XC Hu","year":"2015","unstructured":"Hu, X.C., Zhang, J., Xu, B.H., Cai, L., Ragaz, J., Wang, Z.H., Wang, B.Y., Teng, Y.E., Tong, Z.S., Pan, Y.Y., et al. (2015). Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 16, 436\u2013446.","journal-title":"Lancet Oncol"},{"key":"2946_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-023-06834-7","volume":"625","author":"D Huang","year":"2024","unstructured":"Huang, D., Zhu, X., Ye, S., Zhang, J., Liao, J., Zhang, N., Zeng, X., Wang, J., Yang, B., Zhang, Y., et al. (2024). Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides. Nature 625, 593\u2013602.","journal-title":"Nature"},{"key":"2946_CR19","doi-asserted-by":"publisher","first-page":"D236","DOI":"10.1093\/nar\/gkaa823","volume":"49","author":"W Huang","year":"2021","unstructured":"Huang, W., Ling, Y., Zhang, S., Xia, Q., Cao, R., Fan, X., Fang, Z., Wang, Z., and Zhang, G. (2021a). TransCirc: an interactive database for translatable circular RNAs based on multi-omics evidence. Nucleic Acids Res 49, D236\u2013D242.","journal-title":"Nucleic Acids Res"},{"key":"2946_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12943-019-0969-3","volume":"18","author":"X Huang","year":"2019","unstructured":"Huang, X., Li, Z., Zhang, Q., Wang, W., Li, B., Wang, L., Xu, Z., Zeng, A., Zhang, X., Zhang, X., et al. (2019). Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Mol Cancer 18, 71.","journal-title":"Mol Cancer"},{"key":"2946_CR21","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/jcb.29641","volume":"122","author":"X Huang","year":"2021","unstructured":"Huang, X., Zhang, Q., Hu, H., Jin, Y., Zeng, A., Xia, Y., and Xu, L. (2021b). A novel circular RNA circFN1 enhances cisplatin resistance in gastric cancer via sponging miR-182-5p. J Cell Biochem 122, 1009\u20131020.","journal-title":"J Cell Biochem"},{"key":"2946_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/ncb2731","volume":"15","author":"S Kuchay","year":"2013","unstructured":"Kuchay, S., Duan, S., Schenkein, E., Peschiaroli, A., Saraf, A., Florens, L., Washburn, M.P., and Pagano, M. (2013). FBXL2- and PTPL1-mediated degradation of p110- free p85\u03b2 regulatory subunit controls the PI(3)K signalling cascade. Nat Cell Biol 15, 472\u2013480.","journal-title":"Nat Cell Biol"},{"key":"2946_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12943-020-01259-6","volume":"19","author":"J Li","year":"2020","unstructured":"Li, J., Ma, M., Yang, X., Zhang, M., Luo, J., Zhou, H., Huang, N., Xiao, F., Lai, B., Lv, W., et al. (2020). Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab. Mol Cancer 19, 142.","journal-title":"Mol Cancer"},{"key":"2946_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12943-021-01476-7","volume":"21","author":"Y Ling","year":"2022","unstructured":"Ling, Y., Liang, G., Lin, Q., Fang, X., Luo, Q., Cen, Y., Mehrpour, M., Hamai, A., Liu, Z., Shi, Y., et al. (2022). circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer. Mol Cancer 21, 8.","journal-title":"Mol Cancer"},{"key":"2946_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ygyno.2024.05.002","volume":"187","author":"JF Liu","year":"2024","unstructured":"Liu, J.F., Xiong, N., Wenham, R.M., Wahner-Hendrickson, A., Armstrong, D.K., Chan, N., O\u2019Malley, D.M., Lee, J.M., Penson, R.T., Cristea, M.C., et al. (2024). A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib. Gynecol Oncol 187, 105\u2013112.","journal-title":"Gynecol Oncol"},{"key":"2946_CR26","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/15476286.2019.1600395","volume":"16","author":"M Liu","year":"2019","unstructured":"Liu, M., Wang, Q., Shen, J., Yang, B.B., and Ding, X. (2019). Circbank: a comprehensive database for circRNA with standard nomenclature. RNA Biol 16, 899\u2013905.","journal-title":"RNA Biol"},{"key":"2946_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11912-021-01041-x","volume":"23","author":"F Lynce","year":"2021","unstructured":"Lynce, F., and Nunes, R. (2021). Role of platinums in triple-negative breast cancer. Curr Oncol Rep 23, 50.","journal-title":"Curr Oncol Rep"},{"key":"2946_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.32604\/or.2022.025323","volume":"29","author":"Z Nasrpour Navaei","year":"2021","unstructured":"Nasrpour Navaei, Z., Khalili-tanha, G., Sadra Zangouei, A., Reza Abbaszadegan, M., and Moghbeli, M. (2021). PI3K\/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells. Oncol Res 29, 235\u2013250.","journal-title":"Oncol Res"},{"key":"2946_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/cells8090957","volume":"8","author":"M Nedeljkovi\u0107","year":"2019","unstructured":"Nedeljkovi\u0107, M., and Damjanovi\u0107, A. (2019). Mechanisms of chemotherapy resistance in triple-negative breast cancer\u2014how we can rise to the challenge. Cells 8, 957.","journal-title":"Cells"},{"key":"2946_CR30","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","volume":"29","author":"F Poggio","year":"2018","unstructured":"Poggio, F., Bruzzone, M., Ceppi, M., Pond\u00e9, N.F., La Valle, G., Del Mastro, L., de Azambuja, E., and Lambertini, M. (2018). Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol 29, 1497\u20131508.","journal-title":"Ann Oncol"},{"key":"2946_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.canlet.2015.06.003","volume":"365","author":"S Qu","year":"2015","unstructured":"Qu, S., Yang, X., Li, X., Wang, J., Gao, Y., Shang, R., Sun, W., Dou, K., and Li, H. (2015). Circular RNA: a new star of noncoding RNAs. Cancer Lett 365, 141\u2013148.","journal-title":"Cancer Lett"},{"key":"2946_CR32","doi-asserted-by":"publisher","first-page":"117894","DOI":"10.1016\/j.bmc.2024.117894","volume":"112","author":"D Sahoo","year":"2024","unstructured":"Sahoo, D., Deb, P., Basu, T., Bardhan, S., Patra, S., and Sukul, P.K. (2024). Advancements in platinum-based anticancer drug development: a comprehensive review of strategies, discoveries, and future perspectives. Bioorg Med Chem 112, 117894.","journal-title":"Bioorg Med Chem"},{"key":"2946_CR33","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.ymthe.2019.05.011","volume":"27","author":"Y Sang","year":"2019","unstructured":"Sang, Y., Chen, B., Song, X., Li, Y., Liang, Y., Han, D., Zhang, N., Zhang, H., Liu, Y., Chen, T., et al. (2019). circRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p\/FOXO3a axis in breast cancer. Mol Ther 27, 1638\u20131652.","journal-title":"Mol Ther"},{"key":"2946_CR34","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","volume":"28","author":"DP Silver","year":"2010","unstructured":"Silver, D.P., Richardson, A.L., Eklund, A.C., Wang, Z.C., Szallasi, Z., Li, Q., Juul, N., Leong, C.O., Calogrias, D., Buraimoh, A., et al. (2010). Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28, 1145\u20131153.","journal-title":"J Clin Oncol"},{"key":"2946_CR35","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/annonc\/mdq461","volume":"22","author":"L Staudacher","year":"2011","unstructured":"Staudacher, L., Cottu, P.H., Di\u00e9ras, V., Vincent-Salomon, A., Guilhaume, M.N., Escalup, L., Dorval, T., Beuzeboc, P., Mignot, L., and Pierga, J.Y. (2011). Platinum-based chemotherapy in metastatic triple-negative breast cancer: The Institut Curie experience. Ann Oncol 22, 848\u2013856.","journal-title":"Ann Oncol"},{"key":"2946_CR36","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt, A., Tovey, H., Cheang, M.C.U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018). Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial. Nat Med 24, 628\u2013637.","journal-title":"Nat Med"},{"key":"2946_CR37","doi-asserted-by":"publisher","first-page":"x12","DOI":"10.1093\/annonc\/mdz381","volume":"30","author":"B Verret","year":"2019","unstructured":"Verret, B., Cortes, J., Bachelot, T., Andre, F., and Arnedos, M. (2019). Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol 30, x12\u2013x20.","journal-title":"Ann Oncol"},{"key":"2946_CR38","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks, A.G., and Winer, E.P. (2019). Breast cancer treatment: a review. JAMA 321, 288\u2013300.","journal-title":"JAMA"},{"key":"2946_CR39","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11427-023-2737-2","volume":"68","author":"D Wang","year":"2025","unstructured":"Wang, D., Zuo, S., Ge, J., Qu, H., Wu, J., Yi, N., Shi, L., Wang, Y., Mo, Y., Fan, C., et al. (2025). circTP63-N suppresses the proliferation and metastasis of nasopharyngeal carcinoma via engaging with HSP90AB1 to modulate the YAP1\/Hippo signaling pathway. Sci China Life Sci 68, 689\u2013705.","journal-title":"Sci China Life Sci"},{"key":"2946_CR40","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/ddr.22069","volume":"84","author":"H Wang","year":"2023","unstructured":"Wang, H., Shan, X., Peng, Y., and Zhou, W. (2023). Circular RNAs in the chemoresistance of triple-negative breast cancer: a systematic review. Drug Dev Res 84, 805\u2013814.","journal-title":"Drug Dev Res"},{"key":"2946_CR41","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","volume":"9","author":"RA Wesselhoeft","year":"2018","unstructured":"Wesselhoeft, R.A., Kowalski, P.S., and Anderson, D.G. (2018). Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun 9, 2629.","journal-title":"Nat Commun"},{"key":"2946_CR42","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1592\/phco.29.8.954","volume":"29","author":"ST Wong","year":"2009","unstructured":"Wong, S.T., and Goodin, S. (2009). Overcoming drug resistance in patients with metastatic breast cancer. Pharmacotherapy 29, 954\u2013965.","journal-title":"Pharmacotherapy"},{"key":"2946_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12282-017-0793-9","volume":"25","author":"H Zhang","year":"2018","unstructured":"Zhang, H., Jiang, L., Sun, D., Hou, J., and Ji, Z. (2018). CircRNA: a novel type of biomarker for cancer. Breast Cancer 25, 1\u20137.","journal-title":"Breast Cancer"},{"key":"2946_CR44","doi-asserted-by":"publisher","first-page":"109828","DOI":"10.1016\/j.biopha.2020.109828","volume":"124","author":"F Zheng","year":"2020","unstructured":"Zheng, F., and Xu, R. (2020). CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p\/ABCC1 axis. Biomed Pharmacother 124, 109828.","journal-title":"Biomed Pharmacother"},{"key":"2946_CR45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., and Wu, K. (2023). Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol 16, 100.","journal-title":"J Hematol Oncol"},{"key":"2946_CR46","doi-asserted-by":"publisher","first-page":"188678","DOI":"10.1016\/j.bbcan.2022.188678","volume":"1877","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y., Hu, Y., Tang, C., Guan, X., and Zhang, W. (2022). Platinum-based systematic therapy in triple-negative breast cancer. Biochim Biophys Acta Rev Cancer 1877, 188678.","journal-title":"Biochim Biophys Acta Rev Cancer"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-024-2946-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-024-2946-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-024-2946-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:02:31Z","timestamp":1772791351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-024-2946-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2946"],"URL":"https:\/\/doi.org\/10.1007\/s11427-024-2946-1","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest. All animal experiments were approved by the Sun Yat-sen University Laboratory Animal Care and Use Committee (SYSU-IACUC-2022- B1408). The study was approved by the Medical Ethics Committee of Sun Yat-sen Memorial Hospital, and informed consent was obtained from all patients prior to sample collection (SYMH- 2022-498).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}